Wealthcare Advisory Partners’s Sarepta Therapeutics SRPT Stock Holding History

Wealthcare Advisory Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-113	Closed	-$11K	–	1211
2020 Q1	$11K	Sell	113 -52	-32%	-$5.94K	﹤0.01%	907
2019 Q4	$21K	Hold	165	–	–	﹤0.01%	755
2019 Q3	$12K	Hold	165	–	–	﹤0.01%	885
2019 Q2	$25K	Hold	165	–	–	﹤0.01%	677
2019 Q1	$20K	Sell	165 -35	-18%	-$4.5K	﹤0.01%	663
2018 Q4	$22K	Hold	200	–	–	﹤0.01%	606
2018 Q3	$32K	Sell	200 -1,250	-86%	-$171K	0.01%	568
2018 Q2	$192K	Buy	1,450 +1,250	+625%	+$118K	0.04%	219
2018 Q1	$15K	Hold	200	–	–	﹤0.01%	651
2017 Q4	$11K	Hold	200	–	–	﹤0.01%	662
2017 Q3	$9K	Buy	+200	New	+$7.99K	﹤0.01%	571

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wealthcare Advisory Partners's SRPT Position: Q2 2020 in Review

Wealthcare Advisory Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2020, closing a stake of 113 shares — an estimated $11K sold.

Wealthcare Advisory Partners first reported a position in SRPT in Q3 2017 and held it in 11 quarters. The position peaked at $192K in Q2 2018. 408 funds tracked by Wall St. Rank hold SRPT as of Q2 2020.

Wealthcare Advisory Partners reported no remaining Sarepta Therapeutics position as of Q2 2020 after selling out during the quarter.
Wealthcare Advisory Partners sold 113 Sarepta Therapeutics shares in Q2 2020, an estimated $11K.
Wealthcare Advisory Partners first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 11 quarters.
Wealthcare Advisory Partners's Sarepta Therapeutics position peaked at $192K in Q2 2018.
408 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2020.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2020, filed 29 Jul 2020.